SG10201808312YA - Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines - Google Patents
Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccinesInfo
- Publication number
- SG10201808312YA SG10201808312YA SG10201808312YA SG10201808312YA SG10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA
- Authority
- SG
- Singapore
- Prior art keywords
- aluminum salt
- enhancing
- methods
- adsorbed
- immunostimulation
- Prior art date
Links
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title abstract 4
- 229910052782 aluminium Inorganic materials 0.000 title abstract 4
- 230000003308 immunostimulating effect Effects 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 abstract 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 4
- 239000002502 liposome Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969905P | 2014-03-25 | 2014-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201808312YA true SG10201808312YA (en) | 2018-10-30 |
Family
ID=51302762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201808312YA SG10201808312YA (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
| SG11201607404PA SG11201607404PA (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607404PA SG11201607404PA (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170165358A1 (https=) |
| EP (1) | EP3122379A1 (https=) |
| JP (1) | JP2017509713A (https=) |
| KR (1) | KR20170016315A (https=) |
| CN (1) | CN106535929A (https=) |
| AU (1) | AU2014388299A1 (https=) |
| BR (1) | BR112016021692A2 (https=) |
| CA (1) | CA2943050A1 (https=) |
| MX (1) | MX2016012166A (https=) |
| RU (1) | RU2016141621A (https=) |
| SG (2) | SG10201808312YA (https=) |
| WO (1) | WO2015147899A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化ｐｓａ組成物および方法 |
| EP3484441A4 (en) | 2016-07-15 | 2020-03-18 | President and Fellows of Harvard College | GLYCOLIPID COMPOSITIONS AND METHOD FOR USE |
| JP7385206B2 (ja) * | 2018-12-04 | 2023-11-22 | 国立大学法人大阪大学 | 免疫賦活剤 |
| CA3189004A1 (en) | 2020-07-22 | 2022-01-27 | 3H Bio. Co., Ltd. | A peptide used for immunotherapeutics |
| WO2022081707A1 (en) | 2020-10-13 | 2022-04-21 | The Government Of The United States, As Represented By The Secretary Of The Army | Sars-cov-2 dna vaccine and method of administering thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08506592A (ja) * | 1993-02-19 | 1996-07-16 | スミスクライン・ビーチャム・コーポレイション | ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物 |
| WO1994019013A1 (en) * | 1993-02-19 | 1994-09-01 | Smithkline Beecham Corporation | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| ATE157882T1 (de) * | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| US20090214592A1 (en) * | 2005-02-16 | 2009-08-27 | O'hagan Derek | Adjuvant composition comprising aluminium phosphate and 3D-MPL |
| BRPI0811228A2 (pt) * | 2007-05-24 | 2014-10-21 | Glaxonsmithkline Biolog S A | Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica. |
| SG184188A1 (en) * | 2010-03-26 | 2012-10-30 | Glaxosmithkline Biolog Sa | Hiv vaccine |
-
2014
- 2014-07-09 CN CN201480077507.5A patent/CN106535929A/zh active Pending
- 2014-07-09 RU RU2016141621A patent/RU2016141621A/ru not_active Application Discontinuation
- 2014-07-09 KR KR1020167025974A patent/KR20170016315A/ko not_active Withdrawn
- 2014-07-09 JP JP2017502571A patent/JP2017509713A/ja active Pending
- 2014-07-09 WO PCT/US2014/045940 patent/WO2015147899A1/en not_active Ceased
- 2014-07-09 CA CA2943050A patent/CA2943050A1/en not_active Abandoned
- 2014-07-09 MX MX2016012166A patent/MX2016012166A/es unknown
- 2014-07-09 AU AU2014388299A patent/AU2014388299A1/en not_active Abandoned
- 2014-07-09 BR BR112016021692A patent/BR112016021692A2/pt not_active Application Discontinuation
- 2014-07-09 EP EP14750386.6A patent/EP3122379A1/en not_active Withdrawn
- 2014-07-09 SG SG10201808312YA patent/SG10201808312YA/en unknown
- 2014-07-09 US US15/127,076 patent/US20170165358A1/en not_active Abandoned
- 2014-07-09 SG SG11201607404PA patent/SG11201607404PA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015147899A1 (en) | 2015-10-01 |
| JP2017509713A (ja) | 2017-04-06 |
| KR20170016315A (ko) | 2017-02-13 |
| CA2943050A1 (en) | 2015-10-01 |
| RU2016141621A (ru) | 2018-04-25 |
| MX2016012166A (es) | 2017-03-15 |
| AU2014388299A1 (en) | 2016-10-20 |
| SG11201607404PA (en) | 2016-10-28 |
| CN106535929A (zh) | 2017-03-22 |
| EP3122379A1 (en) | 2017-02-01 |
| BR112016021692A2 (pt) | 2017-08-15 |
| RU2016141621A3 (https=) | 2018-05-11 |
| US20170165358A1 (en) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500947B1 (en) | Crystal form, preparation method and intermediate of dihydropyrido ring compound | |
| PH12017500762A1 (en) | Proflavor delivery particles | |
| EP3484448A4 (en) | MIMETIC SCAFFOLDS OF CELLS HAVING ANTIGEN AND METHODS OF PREPARING AND USING THEM | |
| SG11202003796XA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| SG11201607396WA (en) | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin | |
| EP3154213A4 (en) | Uplink multi-user transmission method in wireless lan system and apparatus therefor | |
| EP3200831A4 (en) | Vaccines having an antigen and interleukin-21 as an adjuvant | |
| SG11202004863QA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| EP3118204A4 (en) | O-phenyl chalcone compound and preparation method and use thereof | |
| MX2017009937A (es) | Cepas fungicas y metodos de uso. | |
| EP3112351A4 (en) | Naphthylamide compound, preparation method and use thereof | |
| MX2017003131A (es) | Metodo para la preparacion de 2-alcoxi ciclohexanol. | |
| MX2022013912A (es) | Procedimientos novedosos para inducir una respuesta inmunitaria. | |
| SG10201808312YA (en) | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines | |
| PL3495153T3 (pl) | Sposób i urządzenie do wytwarzania materiałów warstwowych z porami synchronicznymi | |
| PH12017501795B1 (en) | Pestivirus vaccines for congenital tremors | |
| EP3098313A4 (en) | Method for producing rare fatty acid using novel enzyme, and novel rare fatty acid | |
| EP3110539A4 (en) | Mixing apparatus with stator and method | |
| AU2017219901B2 (en) | Methods of immunogenic modulation | |
| ZA201802565B (en) | New adjuvant and vaccine composition containing the same | |
| EP3110261A4 (en) | Super critical hydrolysis extraction apparatus and hydrolysis method using the same | |
| HK40030428A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| HK40031534A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| HK40030429A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| GB201911959D0 (en) | Immunogenic compositions and uses therefor |